PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Application Number	10/668,057
TRANSMITTAL	Filing Date	September 22, 2003
FORM	First Named Inventor	Anthony D. Sandler
	Art Unit	1634
(to be used for all correspondence after initial filing)	Examiner Name	Bradley L. Sisson
Total Number of Pages in This Submission 21	Attorney Docket Number	17023.032US1
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)									
Amendm Amendm A Extension Express	on of Time F Abandonm	ed eclaration(s)		Drawing(s) Licensing-related Petition Petition to Convert Provisional Applii Power of Attorne Change of Corre Terminal Disclair Request for Refu	ert to a ication ey, Revocat spondence mer und	Address	Copi	Appea of App Appea (Appea Proprii Status Other below	1 pg.) ree (3) references
Docume Reply to Incomple	Missing Pa ete Applicat Reply to Mis	arts/ tion ssing Parts FR 1.52 or 1.53	Rem	<u> </u>			OR AG	ENT	
Firm Name	Firm Name VIKSNINS HARRIS & PADYS PLLP								
Signature	Signature								
Printed name	Printed name Peter L. Mallen								
Date March 20, 2006			Reg. No.			44,894			
I hereby certify the	CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on								
the date shown I	below:	<i>i</i> //			iiiissioner t	or ratents, F	U. DOX	. 1430, /	Nexamina, VA 22313-1450 01
Typed or printed	Typida Muu Lynda Mau Date March 20, 2006				March 20, 2006				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Anthony D. Sandler

Examiner:

Bradley L. Sisson

Serial No.:

10/668,057

Group Art Unit:

1634

Filed:

September 22, 2003

Docket:

17023.032US1

Title:

METHOD FOR PREDICTING TUMOR RECURRENCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Anthony D. Sandler By his Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098 St. Paul, MN 55111 952 876-4094

Date March 20,200 6

Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 2006 day of March, 2006.

Substitute for form 1449A/PTO and/or 1449B/PTO INFORMATION DISCLOSURE



Complete if Known		
Application Number	10/668,057	
Filing Date	September 22, 2003	
First Named Inventor	Sandler	
Group Art Unit	1634	
Examiner Name	Bradley L. Sisson	

Attorney Docket No: 17023.032US1

US PATENT DOCUMENTS				
Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document	
	6,656,684	12/02/2003	Sandler	

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).
	Azuhata et al., "The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma", J Pediatr Surg., 36(12), 1785-1791 (2001).
	Sandler et al., "The survivin:fas ratio is predictive of recurrent disease in neuroblastoma", <u>J</u> Pediatr Surg., <u>37(3)</u> , 507-511 (2002).
	Takamizawa et al., "The survivin:fas ratio in pediatric renal tumors", <u>J Pediatr Surg.</u> , <u>36(1)</u> , 37-42 (2001).